Cisplatin-induced ototoxicity results in significant, permanent hearing loss in pediatric and
adult cancer survivors. Elucidating the mechanisms underlying cisplatin-induced hearing
loss as well as the development of therapies to reduce and/or reverse cisplatin ototoxicity
have been impeded by suboptimal animal models. Clinically, cisplatin is most commonly
administered in multi-dose, multi-cycle protocols. However, many animal studies are
conducted using single injections of high-dose cisplatin, which is not reflective of clinical …